Skip to content

Effect of calorie intervention on renal function and nutritional status in non–dialysis-dependent chronic kidney disease patients

Effect of calorie intervention on renal function and nutritional status in non–dialysis-dependent chronic kidney disease patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020582
Enrollment
Unknown
Registered
2019-01-09
Start date
2019-01-01
Completion date
Unknown
Last updated
2022-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic kidney disease

Interventions

Control group:Regular dietary counseling
Intervention group:Fresubin (120ml/bottle, Fresenius Kabi (Beijing), 560365628705) was used as the non-protein calorie supplement (NPC) for energy replenishment to 30kcal/kg/d.

Sponsors

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged 18-65 years, female and male; 2. Non-diabetic and non-dialysis-dependent CKD patients with stage 1 to 5; 3. The actual daily intake of energy less than recommended(using a 3-day diet record assessment); 4. Voluntary to participate in the study and maintain a stable diet during the trial. And the informed consent form was signed in accordance with the regulations.

Exclusion criteria

Exclusion criteria: 1. Patients with severe gastrointestinal diseases, such as acute gastrointestinal bleeding, intestinal obstruction or severe digestive malabsorption; 2. Patients with diabetes mellitus; 3. Patients with primary diseases such as severe heart disease, severe lung disease, severe brain disease or psychiatric disorders; 4. Patients with active infections; 5. Patients with malignant tumors; 6. Patients intolerated with lactose; 7. Patients who were allergic to any of the ingredients of Fresubin formula; 8. Patients who cannot tolerate nutrients in Fresubin congenital; 9. Obese patients: BMI > 28kg/m^2 or patients with weight loss requirements; 10. Patients with active liver disease; 11. Pregnant or lactating women and perimenopausal women; 12. Being participating other clinical trials.

Design outcomes

Primary

MeasureTime frame
40% reduction in the eGFR compared to baseline;All-cause death;Need for dialysis therapy;

Secondary

MeasureTime frame
The rate of decline in the eGFR;Variations in urine protein excretion rate;Variations in nutrtional status;Variations in mid-arm muscular circumference;Variaitons in serum albumin;Low protein diet compliance rate;Recommended daily energy intake compliance rate;Variaitons in life of quality score;

Countries

China

Contacts

Public ContactYang Qiongqiong

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

yangqq@mail.sysu.edu.cn+86 13826204650

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026